# Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

> **NCT06219499** · PHASE1 · WITHDRAWN · sponsor: **OncoC4, Inc.**

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ONC-841
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06219499
- **Lead sponsor:** OncoC4, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** FDA reviewers asked for Phase 1 study in Oncology subjects, not in healthy volunteers.
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06219499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06219499, "Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06219499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*